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Personalizing treatments to account for genetically mediated differences in drug responses is an
exciting opportunity to improve patient outcomes. In this issue, Soccio et al. reveal new mecha-
nisms by which non-coding variants alter the activity of the anti-diabetic drug rosiglitazone.PPARg, a member of the class of ligand-
responsive transcription factors (TFs)
known as nuclear receptors, is a major
driver of lipid uptake and adipogenesis.
Small-molecule pharmaceuticals target-
ing PPARg have proven to be effective
anti-diabetic agents. Although some indi-
viduals respond well to those treatments
without adverse effects, others experi-
ence reduced efficacy and substantial
side effects. That heterogeneity in treat-
ment response poses a major limitation
for treating type 2 diabetes and is repre-
sentative of the broader challenges facing
physicians when prescribing drugs that
target other nuclear receptors.
Drug responses are highly heritable,
and understanding the genetic mecha-
nisms contributing to that heritability will
improve the application of current drugs
while informing the design of new ones
(Roden and George, 2002). Mutations
that alter protein structure—coding muta-
tions—are a known cause of that heritabil-
ity (Hurley et al., 1991) (Figure 1, top).
Meanwhile, non-coding mutations that
alter steady-state levels of gene expres-
sion are emerging as a major contributor
to the heterogeneity of human pheno-
types, including drug responsiveness
(e.g., Gusev et al., 2014). For example,
genetically altered expression of drug
efflux pumps has been shown to
contribute to chemotherapeutic resis-
tance in some individuals (Patch et al.,
2015) (Figure 1, middle).
Non-coding mutations are typically
thought to act by changing the DNA
sequence of TF binding sites in a way16 Cell 162, July 2, 2015 ª2015 Elsevier Inc.that alters the affinity of the TF to those
sites (McDaniell et al., 2010). In this issue,
Soccio et al. demonstrate that different
alleles of PPARg sites lead to different
transcriptional responses to the anti-dia-
betic drug rosiglitazone (Soccio et al.,
2015) (Figure 1, bottom). In doing so,
they recast the PPARg binding sites as
drug targets and reveal newways inwhich
non-coding variants alter disease risk and
drug responses. Their findings remark-
ably expand the realm of personalized
medicine, particularly for drugs targeting
nuclear receptors.
Mutations in PPARg binding sites are
only part of the story. A variety of addi-
tional TFs interact with PPARg and
contribute to its genomic occupancy.
The co-binding TFs each have their own
DNA binding preferences, complicating
our understanding of how individual non-
coding mutations contribute to PPARg-
mediated effects of rosiglitazone treat-
ment. Soccio et al. show that non-coding
genetic variation not only alters PPARg
occupancy, but also has coordinated
effects on the binding of the associated
TFs C/EBP and the glucocorticoid recep-
tor. Furthermore, disruption of the DNA
binding sequences of any of those TFs
leads to decreased PPARg occupancy.
The observed coordinated effects sup-
port a model in which TFs bind as a com-
plex on a given allele (ENCODE Proect
Consortium, 2012) and indicate that drug
response heterogeneity may also result
frommutations in binding sites for yet-un-
known cooperating TFs. In that manner, it
may be more valuable to consider regula-tory complexes rather than individual
binding sites as the key functional unit
for understanding the genetic contribu-
tions to PPARg and rosiglitazone re-
sponses. Identifying additional members
of PPARg regulatory complexes will also
likely be valuable for predicting genetic
contributions to both type 2 diabetes
and its treatment.
While Soccio et al. find a strong enrich-
ment of allele-specific binding sites near
rosiglitazone-induced genes, they find
no evidence of a similar enrichment near
rosiglitazone-repressed genes. The rela-
tive challenge of identifying the binding
sites responsible for gene repression is
a recurring theme in nuclear receptor
biology (e.g., Reddy et al., 2009). One
possible explanation is that repressive
sites are inherently difficult to assay
due to chromatin structure, epitope avail-
ability, or indirect interaction with the
genome. Alternatively, repression by nu-
clear receptors may be secondary to acti-
vation of direct target genes (Abraham
et al., 2006). Because nearly as many
genes are repressed as are activated by
nuclear receptors, determining the pre-
dominant mechanisms of that repression
will be valuable for ongoing efforts to in-
crease the specificity of nuclear receptor
drugs. For example, secondary factors
may themselves be targets for drugs
that are beneficial either alone or in com-
bination with nuclear-receptor-targeting
drugs. To realize that potential, a revised
understanding of the ways in which nu-
clear receptors repress gene expression
is needed. In particular, determining the
Figure 1. Genetic Variation Affects Drug Responses
(Top) Genetic variants in protein-coding exons can alter protein structure and
subsequent drug responses. In the example of familial glucocorticoid resis-
tance, a mutation in the ligand binding domain of the glucocorticoid receptor
reduces binding of glucocorticoid drugs and subsequent regulation of target
gene expression. (Middle) Regulatory element rearrangements can change the
expression of genes that govern drug responses. For example, a promoter
fusion increases the expression of ABCB1, which encodes the drug efflux
pump MDR1. Increased MDR1 is associated with chemotherapy resistance.
(Bottom) Genetic variation in regulatory elements can disrupt TF binding and
drug responses by altering the affinity of a drug-targeted TF. Soccio et al.
demonstrate that phenomenon by revealing that genetic variants within PPARg
binding sites alter PPARg and cofactor occupancy and alter the response to
rosiglitazone.relative contribution of each
mechanism of repression to
the total repressive effects
will prioritize the most preva-




ants that alter rosiglitazone’s
effects in human cells creates
a new challenge: how do we
determine the resulting organ-
ismal effects? The genetic di-
versity of recombinant inbred
mouse strains makes them a
powerful resource for linking
mouse loci with phenotypes.
Protein sequence and func-
tion are often conserved be-
tween mouse and human,
and therefore it is reasonable
to hypothesize that mutations
in orthologous genes will
have similar phenotypic ef-
fects. There is now growing
evidence that the phenotypic
effects of regulatory variation
may also be conserved be-
tween species (Crowley et al.,
2015).Here, for example, Soc-
cio and colleagues use naturalvariation in metabolic phenotypes be-
tweendisparatemouse strains to implicate
non-coding variation in PPARg binding
sites as contributing to diabetic pheno-
types and rosiglitazone responses. They
then leverage the conserved structure
and function of PPARg between species
to identify genetic variants with similar mo-
lecular effects in human tissues. Their reli-
ance on conserved TF functions between
organisms is an appealing strategy to un-
cover regulatory mechanisms contributing
to type 2 diabetes and one thatmay gener-
alize broadly to other complex human
traits.Together, the findings of Soccio et al.
reveal new mechanisms by which non-
coding variation leads to differences in
drug responses. Because the genetic var-
iants alter the genomic targets of the drug
itself, their findings pave the way to ulti-
mately predict individual transcriptional
responses to a prescribed medication.
When combined with evidence of which
target genes contribute to downstream
drug effects, the transcriptional re-
sponses may form the basis for new ap-
proaches to identify patients who are
most or least likely to respond favorably
to treatment.Cell 162, JulyREFERENCES
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